linjc16/ctgov huggingface dataset:
Auto-PAP Therapy For Improved Fetal Growth

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see whether the presence of night-time breathing disturbances (sleep-disordered breathing) in pregnant women is related to fetal growth patterns. The hypothesis is that fetal growth slows in the 3rd trimester in women with sleep-disordered breathing. Use of a nighttime breathing therapy called auto-PAP could minimize the slowing in fetal growth.

Official Title
-----------------
Auto-PAP Therapy For Improved Fetal Growth

Conditions
-----------------
Obstructive Sleep Apnea, Pregnancy

Intervention / Treatment
-----------------
* Device: Auto-PAP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: at least 18 years old; no more than 20 weeks pregnant; pregnant with one baby; found to have sleep-disordered breathing as measured by a sleep study. If you are found to have severe sleep apnea on the sleep study you will be referred for clinical care instead of participating in the study. Exclusion Criteria: more than 20 weeks pregnant; pregnant with twins, triplets, or more babies; a current smoker, drink alcohol, or use recreational drugs; currently using positive-airway pressure therapy for treatment of obstructive sleep apnea; diagnosed with certain conditions such as bullous lung disease, a bypassed upper airway, pneumothorax (collapsed lung), pneumocephalus (leak of cerebrospinal fluid, the fluid that the brain and spine float in), if you have had recent trauma, or recent nasal surgery.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Auto-PAP Therapy<br> | Device: Auto-PAP<br>* Women will be using the Auto-PAP device nightly from randomization to end of pregnancy<br>|
| No Intervention: No Therapy<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With Slowing of Fetal Growth by 33% or More During the Last Trimester | A slowing of fetal growth will be defined as a slowing of fetal growth by >=33% during the last trimester | 3rd trimester | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence or Absence of Placental Hypoxia | The placenta will be reviewed by a pathologist to determine the presence or absence of areas of hypoxia | At delivery the placenta will be collected and processed. |
Spot Depression Study

Study Overview
=================
Brief Summary
-----------------
This study aims to identify signs of depression and bipolar disorder by measuring changes of certain molecules (biomarkers) that can be detected in dried blood spots. Our goal is to use these biomarkers to develop a diagnostic test to enable early treatment, which can lead to better patient outcomes.

Detailed Description
-----------------
Bipolar disorder and major depression are serious mental health conditions that have a devastating impact on patients, their families and friends, and society. Currently, no laboratory test exists for these disorders. We are trying to develop a molecular test based on blood spots (small spots of blood obtained from patients' fingertips that have been dried on special paper). Volunteers take part by filling out the questionnaire at www.spot-depression.org. They may then be selected to provide a dried blood spot, which can be collected at home using a kit that will be mailed to their address.

Official Title
-----------------
A Blood Test to Identify Persons at Risk of Developing Depression or Bipolar Disorder

Conditions
-----------------
Bipolar Disorder, Depressive Disorder

Intervention / Treatment
-----------------
* Procedure: Online questionnaire and self-administered blood spot


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Residing in the United Kingdom Over 18 years of age Exclusion Criteria: Pregnant or breastfeeding Presence of blood-borne infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Depression<br> | Procedure: Online questionnaire and self-administered blood spot<br> <br> |
| Bipolar disorder<br> | Procedure: Online questionnaire and self-administered blood spot<br> <br> |
| Control<br> | Procedure: Online questionnaire and self-administered blood spot<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of protein concentrations in dried blood spots between patient groups and controls |  | Baseline (at enrollment); no follow-up | 
| Assessment of classification accuracy of protein concentrations in dried blood spots for distinguishing between bipolar disorder and depression |  | Baseline (at enrollment); no follow-up |
Maximum Targeted Ablation of Atrial Flutter

Study Overview
=================
Brief Summary
-----------------
Patients undergoing atrial flutter ablation will be randomized to either the standard ablation approach or voltage targeted approach. Patients will be followed for one year to assess outcome of the ablation technique

Official Title
-----------------
Maximum Targeted Ablation of Atrial Flutter

Conditions
-----------------
Atrial Flutter

Intervention / Treatment
-----------------
* Procedure: radiofrequency catheter ablation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients undergoing TV-IVC isthmus ablatin for atrial flutter Exclusion Criteria: atypical atrial flutter <18 years old any atrial surgery or pacemaker refusal to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: radiofrequency catheter ablation|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
atrial flutter, ablation, voltage targeted
Health-related Quality of Life in General Slovenian Population

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to obtain reference data on health-related quality of life for the functional and symptom scales and single items of the European Organisation for Research and Treatment of Cancer Core Quality-of-Life Questionnaire (EORTC QLQ C30) in a representative sample of Slovenian general population.

Detailed Description
-----------------
A sample of at least 600 people from the Slovenian population, randomly selected, age 18 years and more, representing geografic diversity, will take part in this postal survey. The EORTC QLQ C30 and a questionnaire about demografic data will be send by mail. This is the first study to obtain reference data from the EORTC QLQ C30 in a sample from the general Slovenian population. The results will serve as guidelines for interpreting health-related quality-of-life of different groups of patients.

Official Title
-----------------
Health-related Quality of Life in General Slovenian Poplation Assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Core Quality-of-Life Questionnaire QLQ-C30

Conditions
-----------------
Health-related Quality of Life

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 18 y and more Exclusion Criteria: serious comorbidity previously treated for cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| general population<br>a representative sample from general Slovenian population | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
quality of life, general Slovenian population, EORTC QLQ C30
Triglyceride-Glucose Index In Heart Failure Patients In Sohag University Hospital

Study Overview
=================
Brief Summary
-----------------
study the relationship between Triglyceride glucose index and heart failure patients

Official Title
-----------------
Triglyceride-Glucose Index In Heart Failure Patients In Sohag University Hospital

Conditions
-----------------
Heart Failure, Insulin Resistance

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All Heart Failure patients attend to sohag university hospital aged above 18 year old . Exclusion Criteria: Patients on lipid lowering medications Patients on antidiabetic drugs Patients with comorbidities eg liver cirrhosis or malignancy

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| group 1 heart failure patients<br> | |
| Group 2 controle<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Triglyceride-Glucose Index in Heart Failure Patients | identify the relationship between Triglyceride-Glucose Index and heart failure patients in Sohag University hospital | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
heart failure, triglyceride-glucose index
An Italian Experience on Grade 3b Follicular Lymphoma

Study Overview
=================
Brief Summary
-----------------
Study purpose is to evaluate baseline clinical data, outcome after front-line Rituximab containing chemotherapy and survival in patients with grade 3b Follicular Lymphoma. Also an histological central review is planned in order to re-assess baseline diagnosis according to new 2016 World Health Organization (WHO) criteria.

Official Title
-----------------
An Italian Experience on Grade 3b Follicular Lymphoma

Conditions
-----------------
Grade 3b Follicular Lymphoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of grade 3b Follicular Lymphoma Age > 18 years Front-line treatment with Rituximab containing chemotherapy Availability of histological sample for central review Exclusion Criteria: Other lymphoma diagnosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall Response Rate | Number of patients who achieve Complete Response or Partial Response after treatment | End of front-line treatment (evaluated from diagnosis up to 30 months) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression Free Survival | Time from last response to nearest relapse or follow-up | From first response to last follow-up for at least 2 years (up to 15 years) | 
| Overall Survival | Time to last follow-up or death | Date of last follow-up for at least 2 years (up to 15 years) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Grade 3b Follicular Lymphoma, 2016 WHO Criteria, Front-line treatment, Rituximab
Clinical Predictors of Apnea-hypopnea During Propofol Sedation

Study Overview
=================
Brief Summary
-----------------
To relate two different predictive values of sleep apnea: the STOP score (snoring while sleeping, daytime tiredness, observed breathing stoppages, and high blood pressure) and the estimated respiratory disturbance index (eRDI) with the occurrence of apnea-hypopnea during propofol sedation,thirty four middle-aged male patients who underwent urologic surgery under spinal anaesthesia will be enrolled. Before surgery, patients will be asked to complete a STOP-questionnaire. The eRDI will be calculated using the modified Mallampati's grade, tonsil grade, and the body mass index. After performing spinal anaesthesia, propofol will be infused and adjusted to BIS 70-75. An ApneaLinkTM, which measures airflow through a nasal cannula, will be then applied to estimate the level of apnea-hypopnea.

Detailed Description
-----------------
The investigators will evaluate correlation between STOP scor and AHI(apnea hypopnea index) or eRDI and AHI. After then the investigators will compare AHI severity between high risk group and low risk group subgrouped according to STOP score or eRDI.

Official Title
-----------------
Clinical Predictors of Apnea-hypopnea During Propofol Sedation in Patients Undergoing Spinal Anaesthesia

Conditions
-----------------
Sleep Apnea

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Thirty four males who underwent spinal anaesthesia for transurethral resection of the bladder (TURB) or prostate (TURP) were enrolled in this studyInclusion criteria were American Society of Anaesthesiologists (ASA) physical status of 1-2, and ages of more than 40 years. Exclusion Criteria: Patients with electrocardiographic or simple chest radiographic abnormalities or who had taken medication that could affect their sleep patterns were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Apnea hypopnea index | After surgery, an ApneaLinkTM was connected to a personal computer to record and auto-analyze AHIs. Aopnea was defined as a cessation of airflow for 10s or longer. Hypopnea was defined as a greater than 50% reduction in airflow for 10s or longer. AHI was defined as the number of aopnea and hypopnea incidents per hour. | 1hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sedation, sleep apnea, propofol
Effectiveness of Group CBT in Children With Mixed Psychiatric Disorders

Study Overview
=================
Brief Summary
-----------------
This study aims to examine the immediate and longer-term effectiveness of a group cognitive behavioral therapy intervention (GCBT) in reducing internalizing and externalizing symptoms in children treated for mixed psychiatric disorders in naturalistic clinical settings. Further, the effectiveness of GCBT is compared to a treatment-as-usual condition (TAU). Within this study, it is hypothesized that children with mixed psychiatric disorders will exhibit improvements in parent-rated internalizing problem behavior and parent- and teacher-rated externalizing problem behavior following GCBT.

Official Title
-----------------
Effectiveness of Group CBT on Internalizing and Externalizing Symptoms in Children With Mixed Psychiatric Disorders

Conditions
-----------------
Child Behavior Problem

Intervention / Treatment
-----------------
* Behavioral: The Friends program
* Behavioral: TAU condition


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Helsinki University Hospital child psychiatric outpatient clinic patients with symptoms of anxiety or depression, deficiencies in emotional and behavioral skills impairing functioning, and sufficient social and cognitive skills to participate in group work. Exclusion Criteria: Helsinki University Hospital child psychiatric outpatient clinic patients with excessive physical aggression, excessive physical restlessness to enable skill training, or whose severity of psychiatric symptoms required individual psychotherapy (e.g., acute suicidality or psychosis).

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 13 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: group cognitive behavioral therapy intervention<br> | Behavioral: The Friends program<br>* A GCBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions<br>|
| Experimental: Treatment as usual (TAU)<br> | Behavioral: TAU condition<br>* A TAU waitlist condition during which participants received routine care services tailored to each child individually.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in parent- and teacher rated internalizing and externalizing symptoms | The Child Behavior Check List (CBCL) and the Teacher´s Report Form (TRF) | From referral to GCBT to 6-month follow-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
children, group cognitive behavioral therapy, cognitive behavioral therapy, internalizing symptoms, externalizing symptoms
Fatigue and Interleukin-1 (IL-1) Blockade in Primary Sjøgrens Syndrome

Study Overview
=================
Brief Summary
-----------------
Fatigue is a prevalent phenomenon in Primary Sjøgrens syndrome (PSS). Observations indicate that the cytokine IL-1 is of importance for this phenomenon. In this study the investigators block IL-1 by giving Anakinra (an IL-1 receptor antagonist) to patients with PSS.

Detailed Description
-----------------
A double-blind, placebo-controlled, parallel study of the effect on fatigue of daily injections of Anakinra for one month.

Official Title
-----------------
Fatigue and IL-1 Blockade in Primary Sjøgrens Syndrome

Conditions
-----------------
Fatigue, Primary Sjogren

Intervention / Treatment
-----------------
* Drug: Anakinra
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary Sjøgrens Syndrome according to the European-American criteria Age 18-80 years Written informed consent Exclusion Criteria: Hyper- og hypothyreosis Malignant disease Parkinsons disease Multiple sclerosis Conditions or diseases where Anakinra is contraindicated Mental depression (BDI >13) Neutropenia (<1.5*10.9) Frequent infections Pregnancy, lactating women.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Anakinra<br>Anakinra self-administered s.c. in a dose of 100mg daily | Drug: Anakinra<br>* Anakinra 0.67 ml (100 mg) daily subcutaneously for 4 weeks.<br>* Other names: Kineret;|
| Placebo Comparator: Placebo<br>Placebo self-adminsitered s.c in a dose 0.67ml daily | Drug: Placebo<br>* Saline 0.67 ml daily subcutaneously as placebo drug.<br>* Other names: Saline 0.9%;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fatigue as measured by Fatigue Severity Scale and a visual analogue fatigue scale |  | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inflammatory cytokines and measures of oxidative stress |  | 4 weeks |
Macular Detachment Associated With Intrachoroidal Cavitation

Study Overview
=================
Brief Summary
-----------------
Evaluation of clinical characteristics and surgical outcome for macular detachment associated with peripapillary intrachoroidal cavitation with or without pathologic myopia.

Official Title
-----------------
Macular Detachment Associated With Intrachoroidal Cavitation

Conditions
-----------------
Macular Detachment, Macular Retinoschisis, Intrachoroidal Cavitation

Intervention / Treatment
-----------------
* Other: Vitrectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Eyes with macular detachment or macular retinoschisis Exclusion Criteria: Optic pit maculopathy, vitreomacular traction syndrome

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Vitrectomy<br>Vitreous surgery to treat macular detachment | Other: Vitrectomy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual acuity | The numbers of the patients with visual recovery after surgical intervention | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Optical coherence tomography | Anatomical improvement detected with optical coherence tomography after surgical intervention | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Macular detachment, Macular retinoschisis, Vitrectomy